檢索結果 - David M. Hyman

Refine Results
  1. 1
    Implementing Genome-Driven Oncology

    Implementing Genome-Driven Oncology 由 David M. Hyman, Barry S. Taylor, José Baselga

    出版 2017
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    A view on drug resistance in cancer

    A view on drug resistance in cancer 由 Neil Vasan, José Baselga, David M. Hyman

    出版 2019
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology

    Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology 由 Jessica J. Tao, Alison M. Schram, David M. Hyman

    出版 2017
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  4. 4
    Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology

    Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology 由 Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim, Ajit Suri

    出版 2018
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  5. 5
    Clinical tumour sequencing for precision oncology: time for a universal strategy

    Clinical tumour sequencing for precision oncology: time for a universal strategy 由 Michael L. Cheng, Michael F. Berger, David M. Hyman, David B. Solit

    出版 2018
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    Toward a More Precise Future for Oncology

    Toward a More Precise Future for Oncology 由 Yonina R. Murciano‐Goroff, Barry S. Taylor, David M. Hyman, Alison M. Schram

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Discovery through clinical sequencing in oncology

    Discovery through clinical sequencing in oncology 由 Mark T.A. Donoghue, Alison M. Schram, David M. Hyman, Barry S. Taylor

    出版 2020
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  8. 8
    89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2–Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer

    89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2–Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Negative Primary Bre... 由 Gary A. Ulaner, David M. Hyman, Serge K. Lyashchenko, Jason S. Lewis, Jorge A. Carrasquillo

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials

    Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials 由 David M. Hyman, David B. Solit, Maria E. Arcila, Donavan T. Cheng, Paul Sabbatini, José Baselga, Michael F. Berger, Marc Ladanyi

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Bevacizumab Shows Activity in Patients With Low-Grade Serous Ovarian and Primary Peritoneal Cancer

    Bevacizumab Shows Activity in Patients With Low-Grade Serous Ovarian and Primary Peritoneal Cancer 由 Rachel N. Grisham, Gopa Iyer, Evis Sala, Qin Zhou, Alexia Iasonos, Deborah F. DeLair, David M. Hyman, Carol Aghajanian

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Detailed Echocardiographic Phenotyping in Breast Cancer Patients

    Detailed Echocardiographic Phenotyping in Breast Cancer Patients 由 Hari K. Narayan, Brian S. Finkelman, Benjamin French, Theodore Plappert, David M. Hyman, Amanda M. Smith, Kenneth B. Margulies, Bonnie Ky

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

    A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours 由 Alison M. Schram, Leena Gandhi, Monica Mita, Lars Damstrup, Frank Campana, Manuel Hidalgo, Enrique Grande, David M. Hyman, Rebecca S. Heist

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    The role of systemic chemotherapy in the management of granulosa cell tumors

    The role of systemic chemotherapy in the management of granulosa cell tumors 由 Jane Meisel, David M. Hyman, Anjali R. Jotwani, Qin Zhou, Nadeem R. Abu‐Rustum, Alexia Iasonos, Malcolm C. Pike, Carol Aghajanian

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Detection of an NRAS mutation in Erdheim-Chester disease

    Detection of an NRAS mutation in Erdheim-Chester disease 由 Eli L. Diamond, Omar Abdel‐Wahab, Elena Pentsova, Laetitia Borsu, April Chiu, Julie Teruya‐Feldstein, David M. Hyman, Marc K. Rosenblum

    出版 2013
    獲取全文 獲取全文
    Carta
    加到收藏夾
    Saved in:
  15. 15
    Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies

    Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies 由 Parisa Momtaz, Elena Pentsova, Omar Abdel‐Wahab, Eli L. Diamond, David M. Hyman, Taha Merghoub, Daoqi You, Billel Gasmi, Agnès Viale, Paul B. Chapman

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors

    First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors 由 Jessica J. Tao, Nicholas A. Cangemi, Vicky Makker, Karen A. Cadoo, Joyce F. Liu, Drew Rasco, Willis H. Navarro, Christopher M. Haqq, David M. Hyman

    出版 2019
    獲取全文
    Carta
    加到收藏夾
    Saved in:
  17. 17
    Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions

    Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions 由 Jaclyn F. Hechtman, Ryma Benayed, David M. Hyman, Alexander Drilon, Ahmet Zehir, Denise Frosina, Maria E. Arcila, Snjezana Doğan, David S. Klimstra, Marc Ladanyi, Achim A. Jungbluth

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Response to Selective RET Inhibition With LOXO-292 in a Patient With <i>RET</i> Fusion-Positive Lung Cancer With Leptomeningeal Metastases

    Response to Selective RET Inhibition With LOXO-292 in a Patient With <i>RET</i> Fusion-Positive Lung Cancer With Leptomeningeal Metastases 由 Robin Guo, Mark Schreyer, Jason C. Chang, S. Michael Rothenberg, Dahlia Henry, Paolo Cotzia, Mark G. Kris, Natasha Rekhtman, Robert J. Young, David M. Hyman, Alexander Drilon

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

    A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer 由 Johanna C. Bendell, Anna M. Varghese, David M. Hyman, Todd M. Bauer, Shubham Pant, Sophie Callies, Ji Lin, Ricardo Martínez, Enaksha Wickremsinhe, Aaron Alan Fink, Volker Wacheck, Kathleen N. Moore

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted <sup>89</sup>Zr-Pertuzumab PET/CT

    Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted <sup>89</sup>Zr-Pertuzumab PET/CT 由 Gary A. Ulaner, Jorge A. Carrasquillo, Christopher C. Riedl, Randy Yeh, Vaios Hatzoglou, Dara S. Ross, Komal Jhaveri, Sarat Chandarlapaty, David M. Hyman, Brian M. Zeglis, Serge K. Lyashchenko, Jason S. Lewis

    出版 2020
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: